SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Accepted/In Press date: 23 May 2023

Published date: 6 July 2023

Additional Information: Funding Information: We thank the patients who took part in the trial; the 35 investigators from 11 recruiting centers and their research staff members; colleagues at UK Health Security Agency (UKHSA), including Bassam Hallis, Cathy Rowe and Sue Charlton; and the staff from the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, including P. Boateng, H. Doyle and J. Mason. We also acknowledge the British Society of Blood and Marrow Transplantation and Cellular Therapy and associated centers in the IMPACT network that contributed to the recruitment of patients for the study. The OCTAVE trial was sponsored by the University of Birmingham and supported by the National Core Studies Immunology (NCSi) program and funded by a grant from UK Research and Innovation (UKRI) administered by the Medical Research Council (grant reference number MC_PC_20031). It was designated an Urgent Public Health study by the National Institute of Health Research (NIHR). The trial was designed, initiated and conducted independently by the trial investigators and delivered by the CRCTU, University of Birmingham. PITCH was funded by the UK Department of Health and Social Care as part of the PITCH (Protective Immunity from T cells to Covid-19 in Health workers) Consortium, by UKRI as part of ‘Investigation of proven vaccine breakthrough by SARS-CoV-2 variants in established UK healthcare worker cohorts: SIREN consortium & PITCH Plus Pathway’ MR/W02067X/1, and with contributions from UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC), the Huo Family Foundation and the NIHR (UKRIDHSC COVID-19 Rapid Response Rolling Call, grant reference number COV19-RECPLAS). Staff at the CRCTU are supported by a core funding grant from Cancer Research UK (C22436/A25354) and the IMPACT consortium. E.B. is an NIHR Senior Investigator. D.T. receives funding from a Wellcome-Beit Clinical Research Career Development Fellowship. G.C. received support for the study from NIHR infrastructure at Leeds, UK. M.W. receives funding from the Sidharth and Indira Burman Donation/Imperial (NIHR) Biomedical Research Centre. S.J.D. is funded by an NIHR Global Research Professorship (NIHR300791). T.d.S. is funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z). We would like to acknowledge P. Moss, who led the NCSi program. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care, Public Health England or the US Food and Drug Administration. Funding Information: We thank the patients who took part in the trial; the 35 investigators from 11 recruiting centers and their research staff members; colleagues at UK Health Security Agency (UKHSA), including Bassam Hallis, Cathy Rowe and Sue Charlton; and the staff from the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, including P. Boateng, H. Doyle and J. Mason. We also acknowledge the British Society of Blood and Marrow Transplantation and Cellular Therapy and associated centers in the IMPACT network that contributed to the recruitment of patients for the study. The OCTAVE trial was sponsored by the University of Birmingham and supported by the National Core Studies Immunology (NCSi) program and funded by a grant from UK Research and Innovation (UKRI) administered by the Medical Research Council (grant reference number MC_PC_20031). It was designated an Urgent Public Health study by the National Institute of Health Research (NIHR). The trial was designed, initiated and conducted independently by the trial investigators and delivered by the CRCTU, University of Birmingham. PITCH was funded by the UK Department of Health and Social Care as part of the PITCH (Protective Immunity from T cells to Covid-19 in Health workers) Consortium, by UKRI as part of ‘Investigation of proven vaccine breakthrough by SARS-CoV-2 variants in established UK healthcare worker cohorts: SIREN consortium & PITCH Plus Pathway’ MR/W02067X/1, and with contributions from UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC), the Huo Family Foundation and the NIHR (UKRIDHSC COVID-19 Rapid Response Rolling Call, grant reference number COV19-RECPLAS). Staff at the CRCTU are supported by a core funding grant from Cancer Research UK (C22436/A25354) and the IMPACT consortium. E.B. is an NIHR Senior Investigator. D.T. receives funding from a Wellcome-Beit Clinical Research Career Development Fellowship. G.C. received support for the study from NIHR infrastructure at Leeds, UK. M.W. receives funding from the Sidharth and Indira Burman Donation/Imperial (NIHR) Biomedical Research Centre. S.J.D. is funded by an NIHR Global Research Professorship (NIHR300791). T.d.S. is funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z). We would like to acknowledge P. Moss, who led the NCSi program. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care, Public Health England or the US Food and Drug Administration. Publisher Copyright: © 2023, The Author(s).

Local EPrints ID: 482585

URI: http://eprints.soton.ac.uk/id/eprint/482585

DOI: doi:10.1038/s41591-023-02414-4

ISSN: 1078-8956

PURE UUID: 01ef8986-5906-4eac-ada0-eeaeb18fdbd4

Date deposited: 10 Oct 2023 16:59

Last modified: 05 Jun 2024 19:50